Curium Invests €32M to Expand Prostate Cancer RLT Production
PARIS, France, June 1, 2026 Curium, a global leader in radiopharmaceuticals and nuclear medicine, has announced a strategic investment...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PARIS, France, June 1, 2026 Curium, a global leader in radiopharmaceuticals and nuclear medicine, has announced a strategic investment...
INCHEON, South Korea; ROCKVILLE, Maryland; LONDON — December 21, 2025 — Samsung Biologics, a global contract development and manufacturing...
MIAMI, Fla., December 17, 2025 — Veru Inc., a late-stage biopharmaceutical company, reported its fiscal year 2025 financial results...
CAMBRIDGE, Massachusetts, December 17, 2025 — uBriGene, a leader in advanced biopharmaceutical manufacturing, has launched LVV Turbo™, its next-generation...
